Key result
Targeting atherosclerosis as an inflammatory disease supports individualized molecular diagnosis and management.
Why the study?
Advances in understanding the immune-mediated inflammatory processes and molecular mechanisms in atherosclerosis necessitate an updated clinical approach to diagnosis and management.
This narrative review highlights the role of immune-mediated inflammation, transcriptomics, and epigenetics in the pathogenesis and individualized management of atherosclerosis.
Adipose-immune crosstalk in atherosclerosis warrants no practice change; leaves open transcriptomic targets for prospective validation.
Atherosclerosis is among greatest concerns of contemporary medical science and care, and its dangerous sequel are common knowledge. Atherosclerosis is not just state of excessive activation of innate but involvement also of adaptive immune responses. Adipose tissue cytokines and their diverse shared biological traits with the immune system counterparts orchestrate an immune mediated inflammatory process. Medical progress in transcript-omics and epi-genetics has primarily been driven in recent years by the subclinical chronic inflammation implied in atherosclerosis. Contemporary evidence based medicine has added obligation to individualized address implying molecular approach to diagnosis and management. The context of new knowledge on pathogenesis and rational remediation is pertinent to update clinical approach to atherosclerosis and its complications. The present narrative attempts to incorporate some current perspects for discussion.
No takes yet. Share an insight, caveat, or question.
Pandit et al. (2015) conducted a review in Atherosclerosis. Atherosclerosis is an immune-mediated inflammatory process, and contemporary evidence supports an individualized molecular approach to its diagnosis and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: